首页> 外文期刊>Journal of pharmaceutical sciences. >Drug-Drug Interaction Between Oxycodone and Adjuvant Analgesics in Blood-Brain Barrier Transport and Antinociceptive Effect
【24h】

Drug-Drug Interaction Between Oxycodone and Adjuvant Analgesics in Blood-Brain Barrier Transport and Antinociceptive Effect

机译:羟考酮与血型脑阻隔运输中佐剂镇痛药物的药物 - 药物相互作用及抗血巧效应

获取原文
获取原文并翻译 | 示例
           

摘要

To examine possible blood-brain barrier (BBB) transport interactions between oxycodone and adjuvant analgesics, we firstly screened various candidates in vitro using [3H]pyrilamine, a substrate of the oxycodone transporter, as a probe drug. The uptake of [3H]pyrilamine by conditionally immortalized rat brain capillary endothelial cells (TR-BBB13) was inhibited by antidepressants (amitriptyline, imipramine, clomipramine, amoxapine, and fiuvoxamine), antiarrhythmics (mexi-letine, lidocaine, and flecainide), and ketamine. On the other hand, antiepileptics (carbamazepine, phenytoin, and clonazepam) and corticosteroids (dexamethasone and prednisolone) did not inhibit [sH]pyrilamine uptake, with the exception of sodium valproate. The uptake of oxycodone was significantly inhibited in a concentration-dependent manner by amitriptyline, fiuvoxamine and mexiletine with Ki values of 13, 65, and 44 |jlM, respectively. These Ki values are 5-300 times greater than the human therapeutic plasma concentrations. Finally, we evaluated in vivo interaction between oxycodone and amitriptyline in mice. Antinociceptive effects of oxycodone were increased by coadministration of amitriptyline. The oxycodone concentrations in plasma and brain were not changed by coadministration of amitriptyline. Overall, the results suggest that several adjuvant analgesics may interact with the BBB transport of oxycodone at relatively high concentrations. However, it is unlikely that there would be any significant interaction at therapeutically or pharmacologically relevant concentrations. ?2009 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci
机译:为了检查羟考酮和佐剂镇痛药之间可能的血脑屏障(BBB)传输相互作用,我们首先使用[3H]嘧啶,羟代霉酮转运蛋白的基材,作为探针药物,在体外筛选各种候选物。通过有条件永生化的大鼠脑毛细血管内皮细胞(TR-BBB13)的[3H]嘧啶的摄取(氨素线,含咪唑胺,氯甲胺,阿昔葡萄酒和Fiuvoxamine),抗炎(Mexi-Letine,Lidocaine和Flecainide)抑制氯胺酮。另一方面,抗癫痫药(卡巴马嗪,苯妥林和克隆泮)和皮质类固醇(地塞米松和泼尼松藻)没有抑制嘧啶吸收,除去钠戊酸钠。通过Amitriptyline,Fiuvovoxamine和Mexiletine分别以浓度依赖性的方式显着抑制羟考酮的摄取,分别具有13,65和44 |的Ki值。这些Ki值比人类治疗血浆浓度大5-300倍。最后,我们在小鼠中的羟考酮和阿米利亚尼蛋白质之间的体内相互作用评估。通过亚硝基肽的共同分析增加了羟考酮的抗血质效果。血浆和脑中的羟考酮浓度没有通过亚米蛋白的共同分析来改变。总的来说,结果表明,几种佐剂镇痛药可以在相对高浓度下与羟考酮的BBB传输相互作用。然而,不太可能在治疗或药理学相关浓度下存在任何显着的相互作用。 ?2009 Wiley-Liss,Inc。和美国药剂师协会J Pharm Sci

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号